Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias
Open Access
- 28 April 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (8), 1700-1710
- https://doi.org/10.1182/bloodadvances.2020001657
Abstract
There is no standard or widely effective treatment of patients with moderate aplastic anemia (MAA) or hypo-productive uni-lineage cytopenias (UC). Eltrombopag (EPAG), a small molecule thrombopoietin mimetic, has previously been shown to result in durable multi-lineage hematologic responses with low toxicity in patients with refractory severe aplastic anemia (SAA). Its safety and efficacy in MAA are unknown. This prospective phase 2 study enrolled previously untreated and treated MAA and UC patients with clinically relevant cytopenias. EPAG was administered at doses escalating from 50 to 300 mg/d. Hematologic responses were assessed at 16 to 20 weeks. Responding patients were continued on EPAG until reaching defined robust or stable blood counts. EPAG was reinstituted for relapse. Thirty-four patients were enrolled between 2012 and 2017, including 31 with MAA and 3 with UC. Seventeen patients responded in at least 1 eligible lineage by the primary end point. A striking improvement in anemia was observed in a patient with Diamond-Blackfan anemia. EPAG was well tolerated, and it was discontinued for robust or stable blood counts in 12 of 17 patients after a median of 8 months. A majority required re-initiation of EPAG for declining counts, and all regained response. Two of 34 patients developed non-chromosome 7 bone marrow cytogenetic abnormalities while taking EPAG, without dysplasia or increased blasts. Somatic mutation allele frequencies in cancer genes did not increase overall on EPAG. EPAG is a well-tolerated oral treatment of cytopenias in patients with MAA/UC.Keywords
This publication has 32 references indexed in Scilit:
- Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drugBlood, 2014
- A promising immunosuppressive strategy of cyclosporine alternately combined with levamisole is highly effective for moderate aplastic anemiaAnnals of Hematology, 2013
- Thrombopoietin-Increased DNA-PK-Dependent DNA Repair Limits Hematopoietic Stem and Progenitor Cell Mutagenesis in Response to DNA DamageCell Stem Cell, 2013
- Eltrombopag and Improved Hematopoiesis in Refractory Aplastic AnemiaNew England Journal of Medicine, 2012
- Clinical course of non-severe aplastic anemia in adultsInternational Journal of Hematology, 2010
- Guidelines for the diagnosis and management of aplastic anaemiaBritish Journal of Haematology, 2009
- Current concepts in the pathophysiology and treatment of aplastic anemiaBlood, 2006
- Natural history of moderate aplastic anemia in childrenPediatric Blood & Cancer, 2004
- Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemiaBlood, 2003
- Clinical and laboratory evidence for a trilineage haematopoietic defect in patients with refractory Diamond–Blackfan anaemiaBritish Journal of Haematology, 2000